Uncovering injury-specific proteomic signatures and neurodegenerative risks in single and repetitive traumatic brain injury.

Publication date: Jun 23, 2025

Traumatic brain injury (TBI) is a major public health concern associated with an increased risk of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and chronic traumatic encephalopathy, yet the underlying molecular mechanisms in repetitive TBI remain poorly defined. This study investigates proteomic and behavioral changes following single and repetitive mild TBI in a mouse model, focusing on molecular alterations in the cortex and hippocampus across acute (48 h) and subacute (1 week) stages. Using shotgun proteomics and bioinformatics approaches, including weighted gene co-expression network analysis (WGCNA) and machine learning, we analyzed the proteomic landscapes of TBI-affected brain regions including the hippocampus and the cortex. We assessed motor and cognitive outcomes at 2-, 7-, and 30-days post-injury to explore functional impairments associated with observed molecular changes. Our findings reveal spatio-temporal injury- and time-specific proteomic changes, with a single TBI promoting neuroprotective and repair mechanisms, while repetitive TBI exacerbating neuronal damage and synaptic deficits in the hippocampus. Key deregulated proteins, including Apoa1, ApoE, Cox6a1, and Snca, were linked to neurodegenerative pathways, suggesting molecular connections between TBI and diseases like AD and PD. Behavioral assessments indicated that repetitive TBI significantly impaired motor and cognitive functions, with recovery in motor function by day 30, whereas cognitive deficits persisted. This study provides a detailed analysis of the proteomic and behavioral consequences of TBI, identifying molecular networks as potential biomarkers or therapeutic targets for mitigating long-term cognitive decline associated with repetitive head trauma. These findings underscore the importance of mitochondrial and synaptic integrity in TBI response and suggest that targeting these pathways could reduce neurodegenerative risk following repetitive TBI.

Open Access PDF

Concepts Keywords
Alzheimer Behavioral
Cox6a1 Brain
Neurodegenerative Cognitive
Shotgun Hippocampus
Week Including
Injury
Molecular
Motor
Neurodegenerative
Proteomic
Repetitive
Single
Specific
Tbi
Traumatic

Semantics

Type Source Name
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH Alzheimer’s disease
disease MESH Parkinson’s disease
disease MESH chronic traumatic encephalopathy
disease MESH cognitive decline
pathway REACTOME Signal Transduction
disease MESH neurological disorder
disease MESH oxidative stress
disease MESH neuroinflammation
disease MESH cerebral edema
disease MESH memory loss
drug DRUGBANK Dimethyl sulfone
drug DRUGBANK Coenzyme M
disease MESH inflammation
drug DRUGBANK Pidolic Acid
drug DRUGBANK NADH
drug DRUGBANK ATP
pathway REACTOME Apoptosis
pathway KEGG Platelet activation
pathway KEGG Endocytosis
pathway REACTOME Autophagy
disease MESH death
drug DRUGBANK Galsulfase
disease MESH confusion
pathway REACTOME Translation
disease MESH shock
pathway REACTOME Axon guidance
drug DRUGBANK Isoxaflutole
drug DRUGBANK Potassium
disease MESH spinocerebellar ataxia
pathway KEGG Spinocerebellar ataxia
disease MESH mitochondrial dysfunction
disease MESH multiple sclerosis
disease MESH dementia
drug DRUGBANK Trestolone
pathway REACTOME rRNA processing
pathway REACTOME mRNA Splicing
disease MESH Epilepsy
pathway KEGG Glutathione metabolism
drug DRUGBANK Huperzine B
disease MESH anxiety
disease MESH proteinopathies
drug DRUGBANK Proline
disease MESH uncertainty
disease MESH encephalopathy
disease MESH repression
drug DRUGBANK Water
drug DRUGBANK Ketamine
drug DRUGBANK Xylazine
drug DRUGBANK Isoflurane
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Tromethamine
drug DRUGBANK Aspartame
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Trypsin
drug DRUGBANK Flunarizine
pathway REACTOME Release
pathway REACTOME Digestion
pathway REACTOME Acetylation
drug DRUGBANK Methionine
drug DRUGBANK Amino acids
drug DRUGBANK Silicon dioxide
pathway REACTOME Catecholamine biosynthesis
drug DRUGBANK Mitoquinone
drug DRUGBANK Edaravone
pathway REACTOME Ephrin signaling
drug DRUGBANK Scopolamine
drug DRUGBANK Cholesterol
disease MESH pathogenesis
disease MESH relapsing remitting multiple sclerosis
pathway KEGG Ribosome
disease MESH synucleinopathies
disease MESH tauopathy
disease MESH amyloidosis
drug DRUGBANK L-Asparagine
disease MESH weight gain
disease MESH glioblastoma
disease MESH tumor
pathway REACTOME Reproduction

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *